CERC-301 Misses Primary Endpoint in Phase 2 Trial in Major Depressive Disorder On November 29, 2016, Cerecor, Inc. (CERC) announced topline results for the Phase 2 study of CERC-301 in major ...
BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results